MXCT
MaxCyte Inc
1.20$
-1.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 9.9% | 10.0% | 12.4% | 14.3% | 23.6% | 26.2% | 14.4% | 17.9% | 7.6% | 22.1% | 26.8% | 23.0% | 20.6% | |
| 90.1% | 90.0% | 87.6% | 85.7% | 76.4% | 73.8% | 85.6% | 82.1% | 92.4% | 77.9% | 73.2% | 77.0% | 79.4% | |
| 78.3% | 37.3% | 58.9% | 53.9% | 65.1% | 53.1% | 56.8% | 73.7% | 77.8% | 45.7% | 40.0% | 58.5% | 54.0% | |
| 85.2% | 51.6% | 62.6% | 73.2% | 94.9% | 82.9% | 82.1% | 95.0% | 87.9% | 75.1% | 61.8% | 99.8% | 79.6% | |
| 264.4% | 141.6% | 195.9% | 200.5% | 248.5% | 222.2% | 203.9% | 249.4% | 247.3% | 183.0% | 137.3% | 217.7% | 191.1% | |
| -174.3% | -51.7% | -108.2% | -114.8% | -172.1% | -148.4% | -118.3% | -167.2% | -154.8% | -105.1% | -64.1% | -140.7% | -111.6% | |
| – | 14.7% | – | – | – | – | – | – | – | – | – | – | – | |
| -140.6% | -33.7% | -84.0% | -89.9% | -141.6% | -121.9% | -98.8% | -145.3% | -181.8% | -131.5% | -49.2% | -122.0% | -114.8% | |
| 23,798.1% | 0.0% | 9.4% | – | – | – | – | – | – | – | – | – | – | |
| -140.6% | -33.7% | -84.0% | -89.9% | -141.6% | -121.9% | -98.8% | -145.3% | -181.8% | -131.5% | -49.2% | -122.0% | -114.8% | |
| -160.8% | -26.7% | -73.2% | -78.4% | -128.5% | -104.3% | -86.5% | -130.0% | -169.4% | -113.8% | -38.4% | -122.0% | -104.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.